Table 2.

Approved immune checkpoint inhibitors.

Agents	Type	Company	Approved Year	Indications
Ipilimumab	CTLA-4 mAb	Bristol-Myers Squibb	2011	Melanoma, liver cancer, cellular cancer, colorectal cancer
Pembrolizumab	PD-1 mAb	Merck	2014	Melanoma, lung cancer, head and neck squamous cell carcinoma, Hodgkin’s lymphoma, urothelial carcinoma, esophageal carcinoma, liver cancer, stomach cancer, kidney cancer, cervical cancer, primary mediastinal large B-cell lymphoma, Merckle cell carcinoma
Nivolumab	PD-1 mAb	Bristol-Myers Squibb	2015	Melanoma, lung cancer, head and neck squamous cell carcinoma, Hodgkin’s lymphoma, urothelial carcinoma, liver cancer, kidney cancer, colorectal cancer
Cemiplimab	PD-1 mAb	Sanofi SA/Regeneron	2018	Cutaneous squamous cell carcinoma
Atezolizumab	PD-L1 mAb	Genentech	2016	Urothelial carcinoma, lung cancer
Avelumab	PD-L1 mAb	Merck Serono	2017	Urothelial carcinoma, renal carcinoma, highly malignant skin cancer
Durvalumab	PD-L1 mAb	Medimmune	2017	Urothelial carcinoma